Genmab A/S (NASDAQ:GMAB) Receives Consensus Rating of “Hold” from Brokerages

Shares of Genmab A/S (NASDAQ:GMAB) have been given a consensus rating of “Hold” by the thirteen ratings firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $49.50.

A number of research firms recently commented on GMAB. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Thursday, June 27th. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a research note on Tuesday, March 26th. BTIG Research lifted their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Finally, Truist Financial upped their target price on shares of Genmab A/S from $50.00 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, June 4th.

Institutional Trading of Genmab A/S

Several hedge funds and other institutional investors have recently modified their holdings of the company. Pinnacle Bancorp Inc. boosted its position in shares of Genmab A/S by 315.8% during the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after buying an additional 638 shares during the period. Russell Investments Group Ltd. boosted its position in Genmab A/S by 137.7% during the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after acquiring an additional 544 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Genmab A/S by 194.0% during the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after acquiring an additional 749 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Genmab A/S in the first quarter valued at approximately $43,000. Finally, Principal Securities Inc. bought a new stake in shares of Genmab A/S in the fourth quarter worth $77,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Trading Up 1.0 %

Shares of NASDAQ:GMAB opened at $25.15 on Friday. Genmab A/S has a 1-year low of $24.53 and a 1-year high of $42.72. The stock has a market capitalization of $16.63 billion, a P/E ratio of 20.96, a P/E/G ratio of 0.91 and a beta of 0.97. The business has a 50-day moving average price of $27.69 and a two-hundred day moving average price of $28.94.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. Genmab A/S had a net margin of 30.74% and a return on equity of 18.90%. The business had revenue of $603.30 million for the quarter, compared to analyst estimates of $594.23 million. As a group, equities analysts predict that Genmab A/S will post 1.11 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.